# To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects

> **NCT06485401** · PHASE1 · COMPLETED · sponsor: **Jiaxing AnDiCon Biotech Co.,Ltd** · enrollment: 16 (actual)

## Conditions studied

- Influenza Type A
- Influenza Type B

## Interventions

- **DRUG:** ADC189

## Key facts

- **NCT ID:** NCT06485401
- **Lead sponsor:** Jiaxing AnDiCon Biotech Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-14
- **Primary completion:** 2024-06-21
- **Final completion:** 2024-06-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485401, "To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function Subjects". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06485401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*